Lisata Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 25
- Market Cap
- -
- Website
- http://www.lisata.com
- Introduction
Lisata Therapeutics, Inc. is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. It also actuates thi...
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
- Conditions
- Interventions
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 291
- Registration Number
- NCT01508910
NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT01495364
- Locations
- 🇺🇸
St. Joseph's Research Institute, Atlanta, Georgia, United States
🇺🇸University of Maryland Med Center, Baltimore, Baltimore, Maryland, United States
🇺🇸Westchester Medical Center, Valhalla, New York, United States
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Registration Number
- NCT00814593
- Locations
- 🇺🇸
Hoag Cancer Institute at Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)
- Conditions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2018-11-28
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00545610
- Locations
- 🇺🇸
Caritas St. Elizabeth´s Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Holy Cross Hospital, Fort Lauderdale, Florida, United States
ACT34-CMI -- Adult Autologous CD34+ Cells
- Conditions
- Interventions
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 321
- Registration Number
- NCT00300053
- Locations
- 🇺🇸
Northwestern University Medical Center, Bluhm Cardiovascluar Institute, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Scripps Memorial Hospital, La Jolla, California, United States
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00012064
- Locations
- 🇺🇸
Hoag Cancer Center at Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Vaccine Therapy in Treating Patients With Kidney Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT00014131
- Locations
- 🇺🇸
Hoag Cancer Center at Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States